Skip to content
ModernDoc
Get the app
Condition research / Explore another topicSaved preview · Not clinically reviewed
Asthma.

The long view. The new questions.
A clearer understanding.

Study reading

Immunotherapy improved allergic asthma but increased systemic reactions

A meta-analysis combined 28 randomized trials evaluating allergen-specific immunotherapy for allergic asthma. The pooled results reported improved asthma symptoms and reduced medication use. However, immunotherapy significantly increased systemic reactions, so the reported benefits must be read alongside this harm. Systemic reactions increased significantly, so the review does not support describing immunotherapy as free of important harms.

Evidence period: 2026 Dec1 min readAI-written · Not clinically reviewed

Saved revision 1 · · Revision history

A meta-analysis combined 28 randomized trials evaluating allergen-specific immunotherapy for allergic asthma. The pooled results reported improved asthma symptoms and reduced medication use. However, immunotherapy significantly increased systemic reactions, so the reported benefits must be read alongside this harm.

What the study found

A meta-analysis combined 28 randomized trials evaluating allergen-specific immunotherapy for allergic asthma. The pooled results reported improved asthma symptoms and reduced medication use. However, immunotherapy significantly increased systemic reactions, so the reported benefits must be read alongside this harm. Source ↗

Immunotherapy improved asthma symptoms, medication scores and FEV1, but it also increased systemic reactions. Source ↗

Who and what was studied

The included randomized trials involved people with allergic asthma and were analyzed by age and allergen type. Source ↗

The review compared subcutaneous and sublingual immunotherapy, reporting greater efficacy with the subcutaneous route. Source ↗

What remains uncertain

Systemic reactions increased significantly, so the review does not support describing immunotherapy as free of important harms. Source ↗

Follow the evidence.

Source links and automated passage checks do not establish clinical review.

Supporting passages: Immunotherapy improved allergic asthma but increased systemic reactions

A total of 28 RCTs were included in the meta-analysis. AIT significantly improved asthma symptoms (p < 0.001), with SCIT showing greater efficacy than SLIT. Treatment duration and age did not significantly impact the outcomes. AIT was effective against both house dust mite and grass pollen allergies. It also notably improved medication scores (p < 0.001) and positively impacted FEV1 (p < 0.001). Regarding safety, AIT did not increase the total number of local side effects but significantly increased systemic reactions.

PMID 41784325 · abstract-3
Supporting passages: A meta-analysis combined 28 randomized trials evaluating allergen-specific immunotherapy for allergic asthma. The pooled results reported improved asthma symptoms and reduced medication use. However, immunotherapy significantly increased systemic reactions, so the reported benefits must be read alongside this harm. Systemic reactions increased significantly, so the review does not support describing immunotherapy as free of important harms.

A comprehensive search across PubMed, Cochrane Library, Embase and Web of Science was conducted. Randomized controlled trials (RCTs) evaluating AIT for allergic asthma were included. Data analysis was performed using RevMan 5.3, with evaluations for heterogeneity and publication bias. Subgroup analyses were stratified based on different treatment type, duration, age and allergen type (house dust mites vs. grass pollen).

PMID 41784325 · abstract-2

A total of 28 RCTs were included in the meta-analysis. AIT significantly improved asthma symptoms (p < 0.001), with SCIT showing greater efficacy than SLIT. Treatment duration and age did not significantly impact the outcomes. AIT was effective against both house dust mite and grass pollen allergies. It also notably improved medication scores (p < 0.001) and positively impacted FEV1 (p < 0.001). Regarding safety, AIT did not increase the total number of local side effects but significantly increased systemic reactions.

PMID 41784325 · abstract-3

AIT is effective in improving asthma symptoms and reducing medication use, with subcutaneous immunotherapy being more efficacious than sublingual immunotherapy. The effectiveness varies by allergen type, with no substantial differences across age groups and treatment durations.

PMID 41784325 · abstract-4
Supporting passages: A meta-analysis combined 28 randomized trials evaluating allergen-specific immunotherapy for allergic asthma. The pooled results reported improved asthma symptoms and reduced medication use. However, immunotherapy significantly increased systemic reactions, so the reported benefits must be read alongside this harm.

A comprehensive search across PubMed, Cochrane Library, Embase and Web of Science was conducted. Randomized controlled trials (RCTs) evaluating AIT for allergic asthma were included. Data analysis was performed using RevMan 5.3, with evaluations for heterogeneity and publication bias. Subgroup analyses were stratified based on different treatment type, duration, age and allergen type (house dust mites vs. grass pollen).

PMID 41784325 · abstract-2

A total of 28 RCTs were included in the meta-analysis. AIT significantly improved asthma symptoms (p < 0.001), with SCIT showing greater efficacy than SLIT. Treatment duration and age did not significantly impact the outcomes. AIT was effective against both house dust mite and grass pollen allergies. It also notably improved medication scores (p < 0.001) and positively impacted FEV1 (p < 0.001). Regarding safety, AIT did not increase the total number of local side effects but significantly increased systemic reactions.

PMID 41784325 · abstract-3

AIT is effective in improving asthma symptoms and reducing medication use, with subcutaneous immunotherapy being more efficacious than sublingual immunotherapy. The effectiveness varies by allergen type, with no substantial differences across age groups and treatment durations.

PMID 41784325 · abstract-4
Supporting passages: A meta-analysis combined 28 randomized trials evaluating allergen-specific immunotherapy for allergic asthma. The pooled results reported improved asthma symptoms and reduced medication use. However, immunotherapy significantly increased systemic reactions, so the reported benefits must be read alongside this harm.

A comprehensive search across PubMed, Cochrane Library, Embase and Web of Science was conducted. Randomized controlled trials (RCTs) evaluating AIT for allergic asthma were included. Data analysis was performed using RevMan 5.3, with evaluations for heterogeneity and publication bias. Subgroup analyses were stratified based on different treatment type, duration, age and allergen type (house dust mites vs. grass pollen).

PMID 41784325 · abstract-2

A total of 28 RCTs were included in the meta-analysis. AIT significantly improved asthma symptoms (p < 0.001), with SCIT showing greater efficacy than SLIT. Treatment duration and age did not significantly impact the outcomes. AIT was effective against both house dust mite and grass pollen allergies. It also notably improved medication scores (p < 0.001) and positively impacted FEV1 (p < 0.001). Regarding safety, AIT did not increase the total number of local side effects but significantly increased systemic reactions.

PMID 41784325 · abstract-3

AIT is effective in improving asthma symptoms and reducing medication use, with subcutaneous immunotherapy being more efficacious than sublingual immunotherapy. The effectiveness varies by allergen type, with no substantial differences across age groups and treatment durations.

PMID 41784325 · abstract-4
Supporting passages: Immunotherapy improved asthma symptoms, medication scores and FEV1, but it also increased systemic reactions.

A total of 28 RCTs were included in the meta-analysis. AIT significantly improved asthma symptoms (p < 0.001), with SCIT showing greater efficacy than SLIT. Treatment duration and age did not significantly impact the outcomes. AIT was effective against both house dust mite and grass pollen allergies. It also notably improved medication scores (p < 0.001) and positively impacted FEV1 (p < 0.001). Regarding safety, AIT did not increase the total number of local side effects but significantly increased systemic reactions.

PMID 41784325 · abstract-3
Supporting passages: The included randomized trials involved people with allergic asthma and were analyzed by age and allergen type.

This meta-analysis aims to evaluate the efficacy and safety of allergen-specific immunotherapy (AIT) in treating allergic asthma.

PMID 41784325 · abstract-1

A comprehensive search across PubMed, Cochrane Library, Embase and Web of Science was conducted. Randomized controlled trials (RCTs) evaluating AIT for allergic asthma were included. Data analysis was performed using RevMan 5.3, with evaluations for heterogeneity and publication bias. Subgroup analyses were stratified based on different treatment type, duration, age and allergen type (house dust mites vs. grass pollen).

PMID 41784325 · abstract-2
Supporting passages: The review compared subcutaneous and sublingual immunotherapy, reporting greater efficacy with the subcutaneous route.

A comprehensive search across PubMed, Cochrane Library, Embase and Web of Science was conducted. Randomized controlled trials (RCTs) evaluating AIT for allergic asthma were included. Data analysis was performed using RevMan 5.3, with evaluations for heterogeneity and publication bias. Subgroup analyses were stratified based on different treatment type, duration, age and allergen type (house dust mites vs. grass pollen).

PMID 41784325 · abstract-2

A total of 28 RCTs were included in the meta-analysis. AIT significantly improved asthma symptoms (p < 0.001), with SCIT showing greater efficacy than SLIT. Treatment duration and age did not significantly impact the outcomes. AIT was effective against both house dust mite and grass pollen allergies. It also notably improved medication scores (p < 0.001) and positively impacted FEV1 (p < 0.001). Regarding safety, AIT did not increase the total number of local side effects but significantly increased systemic reactions.

PMID 41784325 · abstract-3
Supporting passages: Systemic reactions increased significantly, so the review does not support describing immunotherapy as free of important harms.

A total of 28 RCTs were included in the meta-analysis. AIT significantly improved asthma symptoms (p < 0.001), with SCIT showing greater efficacy than SLIT. Treatment duration and age did not significantly impact the outcomes. AIT was effective against both house dust mite and grass pollen allergies. It also notably improved medication scores (p < 0.001) and positively impacted FEV1 (p < 0.001). Regarding safety, AIT did not increase the total number of local side effects but significantly increased systemic reactions.

PMID 41784325 · abstract-3
  1. Efficacy and safety of allergen-specific immunotherapy for allergic asthma: a meta-analysis comparing sublingual and subcutaneous routes across allergen types and age groups. ↗

    2026 Dec

    Source checked: 2026-09-15

There’s more to the story.

Study readings

Two active programs showed similar asthma-control improvements

Physically inactive adults with moderate-to-severe uncontrolled asthma were randomized to treadmill training or a behavioral program to increase daily activity. Both groups showed clinically meaningful improvements in asthma control and quality of life, maintained at four-month follow-up. Because two active programs were compared, these changes do not establish benefit over receiving no program. Because the trial compared only two active programs, improvement in both does not establish benefit over no program; similar results also do not prove the programs equivalent. The cohort was physically inactive and was predominantly women with several reported health characteristics, so the same results are not established for everyone with asthma. With 27 and 25 participants in the groups, these estimates remain uncertain and need confirmation in larger studies. The last reported assessment was after four-month follow-up, so outcomes beyond that point are not established.

2 min read · 2026 Dec

Study readings

Past asthma exacerbations were linked to greater school readiness

Researchers assessed school asthma resources for children aged 5 to 13 in a larger trial cohort. Schools often knew about a child’s diagnosis, but reliever medication, holding chambers and care plans were less common. More preceding-year asthma exacerbations were associated with higher readiness; this baseline association cannot show whether readiness changed asthma risk. The cohort was overwhelmingly Black and non-Hispanic, and many had a recent asthma emergency-department visit, so the same pattern is not established for all children with asthma. This was a baseline observational analysis of preceding-year events, so the association cannot establish that school readiness caused or prevented asthma exacerbations.

2 min read · 2026 Sep 1

A publication for curiosity.

AI-written. Not clinically reviewed. Selected sources, not a complete review. No personal treatment matching.

Article revisions preserve earlier writing. Article dates and source-check dates describe different events. Email updates and automatic research refresh are unavailable during this pilot.